Abstract:Cerebral small vessel disease (SVD), as defined by neuroimaging characteristics such as white matter hyperintensities (WMHs), cerebral microhemorrhages (CMHs), and lacunar infarcts, is highly prevalent and has been associated with dementia risk and other clinical sequelae. Although conditions such as hypertension are known to contribute to SVD, little is known about the diverse set of subclinical biological processes and molecular mediators that may also influence the development and progression of SVD. To better understand the mechanisms underlying SVD and to identify novel SVD biomarkers, we used a large-scale proteomic platform to relate 4,877 plasma proteins to MRI-defined SVD characteristics within 1,508 participants of the Atherosclerosis Risk in Communities (ARIC) Study cohort. Our proteome-wide analysis of older adults (mean age: 76) identified 13 WMH-associated plasma proteins involved in synaptic function, endothelial integrity, and angiogenesis, two of which remained associated with late-life WMH volume when measured nearly 20 years earlier, during midlife. We replicated the relationship between 9 candidate proteins and WMH volume in one or more external cohorts; we found that 11 of the 13 proteins were associated with risk for future dementia; and we leveraged publicly available proteomic data from brain tissue to demonstrate that a subset of WMH-associated proteins was differentially expressed in the context of cerebral atherosclerosis, pathologically-defined Alzheimers disease, and cognitive decline. Bidirectional two-sample Mendelian randomization analyses examined the causal relationships between candidate proteins and WMH volume, while pathway and network analyses identified discrete biological processes (lipid/cholesterol metabolism, NF-kB signaling, hemostasis) associated with distinct forms of SVD. Finally, we synthesized these findings to identify two plasma proteins, oligodendrocyte myelin glycoprotein (OMG) and neuronal pentraxin receptor (NPTXR), as top candidate biomarkers for elevated WMH volume and its clinical manifestations.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to identify novel biomarkers and disease pathways associated with cerebral small vessel disease (SVD) through large - scale proteomics analysis. Specifically, the researchers utilized a large - scale proteomics platform to correlate 4,877 plasma proteins with MRI - defined SVD features, such as white matter hyperintensities (WMHs), cerebral microbleeds (CMHs) and lacunar infarcts, etc., in order to better understand the underlying mechanisms of SVD and discover new SVD biomarkers. ### Main research questions: 1. **Identify novel biomarkers**: Through large - scale proteomics analysis, identify new biomarkers associated with SVD, especially proteins related to white matter hyperintensities (WMHs). 2. **Explore disease pathways**: Study the role of these proteins in the pathogenesis of SVD and whether they are associated with other diseases (such as Alzheimer's disease). 3. **Verify and expand findings**: Verify these findings in external cohorts and further explore the functions and interactions of these proteins through system - level analysis (such as pathway analysis and network analysis). 4. **Causality analysis**: Use Mendelian randomization methods to explore the causal relationship between candidate proteins and SVD. ### Specific research contents: - **Sample characteristics**: The study included 1,508 participants in the ARIC study cohort with an average age of 76 years. - **Proteomics analysis**: The levels of nearly 5,000 proteins were measured by SomaScan multiplex proteomics technology and correlated with MRI - defined SVD features. - **Main findings**: Thirteen proteins significantly associated with WMH volume were identified, among which oligodendrocyte myelin glycoprotein (OMG) and neuronal pentraxin receptor (NPTXR) showed the strongest association. - **External validation**: The relationship between these proteins and WMH volume was verified in multiple external cohorts. - **Function and pathway analysis**: Through pathway analysis and network analysis, the biological processes in which these proteins are involved, such as lipid/cholesterol metabolism, NF - kB signaling and hemostasis, etc., were revealed. - **Causality analysis**: Mendelian randomization methods were used to explore the causal relationship between candidate proteins and WMH volume. ### Conclusion: This study, through large - scale proteomics analysis, not only identified novel biomarkers associated with SVD, but also revealed the potential roles of these proteins in the pathogenesis of SVD. These findings provide important scientific basis for future clinical applications and treatment strategies.

Plasma proteome-wide analysis of cerebral small vessel disease identifies novel biomarkers and disease pathways